Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Identifier
M10-315
CT.gov Identifier
NCT00710580
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dermatology - Psoriasis (PsO)
    • Study Drug
  • ABT-874
  • etanercept
  • placebo
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of Psoriasis for 6 MO * BSA 10% * PASI 12 or above * PGA 3 or above
    Exclusion Criteria:
    * Previous exposure to either etanercept or ABT-874

    Protocol Summary

    Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 9984
    Birmingham, Alabama, United States, 35205
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 10605
    Birmingham, Alabama, United States, 35233
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 10001
    Scottsdale, Arizona, United States, 85251
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 10502
    Little Rock, Arkansas, United States, 72205
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 9985
    Bakersfield, California, United States, 93309
    Status
    Not applicable
    Location
    Site Reference ID/Investigator# 10661
    Irvine, California, United States, 92697
    Status
    Not applicable
    Showing {first} - {last} of {total} Results